Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
-- Orderly Changes — Including Adding a Majority of New Stockholder-Friendly Independent Directors — Have Already Been Implemented...
-
MORRIS PLAINS, N.J., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today commenced mailing of a letter to stockholders in connection with its...
-
-- Corrects venBio Mischaracterizations and Highlights Commitment to Maximize Near-Term Value for Stockholders -- -- Urges Stockholders to Minimize Near-Term Disruption by Voting on the WHITE Proxy...
-
Highlights New, Independent Board Focused on Maximizing Stockholder Value at Critical Near-Term Value-Inflection PointUrges Stockholders to Minimize Near-Term Disruption and Support New Board’s...
-
MORRIS PLAINS, N.J., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today commenced mailing of a letter to stockholders in connection with its...
-
-- Details Preclinical and Clinical Progress in Advancing IMMU-114, IMMU-130, IMMU-140, and Immuno-Oncology Program -- -- Expresses Confidence in Near- and Long-Term Growth Prospects for Stockholders...
-
-- IMMU-132 Provides Opportunity for Significant Near-Term Value Creation -- -- Submission for Accelerated Approval Application to FDA for Patients with Metastatic TNBC Remains on Track for mid-2017...
-
Urges Stockholders to Vote “FOR” Each of Immunomedics’ Highly-Qualified Director Nominees on the WHITE Proxy Card venBio Rejects Constructive, Stockholder-Friendly Settlement Proposal and Insists on...
-
MORRIS PLAINS, N.J., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) today announced that, based on a preclinical study, the encouraging efficacy observed with sacituzumab...
-
-- Appoints Four New, Highly Qualified Independent Directors: Jason Aryeh, Dr. Geoffrey Cox, Robert Forrester and Bob Oliver --– -- Announces Chairman and CEO Succession Plans --– -- Mails Letter...